
This filing relates to the offer and sale from time to time by the selling stockholders of up to 5.74M shares of common stock. The company is not selling any
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| SRZN | Surrozen | 31.74 | 17.45 | 122.07% |
| Name | Price | % Change | |
|---|---|---|---|
| $31.74 | +122.07% |

This filing relates to the offer and sale from time to time by the selling stockholders of up to 5.74M shares of common stock. The company is not selling any

Surrozen ( ($SRZN) ) has issued an announcement. On November 13, 2026, Surrozen, Inc. entered into an underwriting agreement with Morgan Stanley & Co. LLC, Guggenheim Securities, LLC and Cantor

Surrozen (SRZN) announced the pricing of an underwritten offering of 1,894,540 shares of its common stock at an offering price of $31.67 per share. The gross proceeds to Surrozen from

Guggenheim raised the firm’s price target on Surrozen (SRZN) to $80 from $42 and keeps a Buy rating on the shares. Following Merck’s (MRK) full disclosure of Remigromig in DME

Net loss was $129.7M, including non-cash loss of $113M on changes in fair value of tranche liability and warrant liabilities, for the quarter ended September 30, 2026, compared to a

Cantor Fitzgerald raised the firm’s price target on Surrozen (SRZN) to $62 from $40 and keeps an Overweight rating on the shares. Surrozen’s Q3 update and positive Wnt mechanism outlook

Surrozen, Inc. (SRZN) is scheduled to report 3rd quarter earnings on 11/11/2026. Regarding Q3 estimates, Wall Street analysts expect Surrozen, Inc. to post earnings of -$1.10 per share. Revenue expectations

The latest announcement is out from Surrozen ( ($SRZN) ). On October 20, 2026, Surrozen closed the second and final tranche of its March 2025 private placement, raising approximately $95.1

William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on SRZN stock, giving a Buy rating on September 26. Lachlan Hanbury Brown has given his Buy rating due

Surrozen ( ($SRZN) ) has provided an announcement. Surrozen, Inc., a biotech developer of Wnt-modulating antibody therapies, reported on October 2, 2026, that the U.S. Food and Drug Administration cleared
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 25, 2027TBA | $571.47M | $-1.04 | $250.00K | -0.01 | -0.69 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.